Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma

doi:10.4251/wjgo.v12.i6.663

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 6

This Article

(339)

(429)

(0)

(12)

(2)

(8685)

(19)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Observational Study

World J Gastrointest Oncol. Jun 15, 2020; 12(6): 663-676
Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.663

Table 3 Treatment-emergent and drug-related adverse events

Adverse event			Participants, n (%)
Adverse event	Grade I	Grade II	Grade III	Grade IV
Hematological
Decreased platelet count	14 (21.2)	8 (12.1)	3 (4.5)	0 (0)
Decreased neutrophil count	15 (22.7)	11 (16.7)	2 (3.0)	0 (0)
Non-hematological
Elevated alanine	30 (45.5)	8 (12.1)	4 (6.1)	4 (6.1)
Elevated serum bilirubin	20 (30.3)	26 (39.4)	5 (7.6)	0 (0)
Nausea and vomiting	32 (48.5)	8 (12.1)	0 (0)	0 (0)
Pain	29 (43.9)	11 (16.7)	0 (0)	0 (0)
Fever	4 (6.1)	2 (3.0)	0 (0)	0 (0)
Diarrhea	10 (15.2)	6 (9.1)	0 (0)	0 (0)
Hand-foot skin reaction	7 (10.6)	16 (24.2)	4 (6.1)	0 (0)
Neurotoxicity	18 (27.3)	7 (10.6)	0 (0)	0 (0)

Data are the number of patients, with percentages in parentheses; all participants were treated with hepatic arterial infusion chemotherapy (oxaliplatin, 5-fluorouracil, and folinic acid) after transarterial chemoembolization combined with sorafenib for intermediate and advanced hepatocellular carcinoma.

Full Size Table

Citation: Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676
URL: https://www.wjgnet.com/1948-5204/full/v12/i6/663.htm
DOI: https://dx.doi.org/10.4251/wjgo.v12.i6.663

Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676 [PMID: 32699581 DOI: 10.4251/wjgo.v12.i6.663]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.